NT_1170x120_1-11-18

U.S. Food and Drug Administration (FDA)

Hy-Vee suspends sale of Zantac brand, Topcare brand ranitidine products

Hy-Vee suspends sale of Zantac brand, Topcare brand ranitidine products

WEST DES MOINES, Iowa — Hy-Vee has temporarily suspended the sale of all over-the-counter Zantac brand and Topcare brand ranitidine products. This action is being taken out of an abundance of caution due to a recent industry-wide product alert from the U.S. Food and Drug Administration (FDA) that ranitidine products may contain a low level

New label requirements call for adherence and label literacy

New label requirements call for adherence and label literacy

WASHINGTON — Due to changes in the American diet and updates in nutrition science, the U.S. Food and Drug Administration (FDA) mandated new label requirements for foods and dietary supplements. The label changes, ranging from measuring folic acid in micrograms of dietary folate equivalents (DFEs) to including added sugar and its percentage of daily value,

FDA approves new preventive treatment for migraines

FDA approves new preventive treatment for migraines

WASHINGTON — The U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab-aooe) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Aimovig is the first FDA-approved preventive migraine treatment in a new class of drugs that work by blocking the activity of calcitonin gene-related peptide, a molecule that